Skip to Content

Bilastine Approval Status

FDA Approved: No
Generic name: Bilastine
Company: Inspire Pharmaceuticals, Inc.
Treatment for: Allergic Rhinitis

Bilastine is an investigational selective histamine H1 receptor antagonist for the treatment of allergic rhinitis.

In January 2008, Inspire Pharmaceuticals, Inc. announced the termination of the licensing agreement with FAES Farma, S.A. and the cessation of the development and commercialization of bilastine.

Development Status and FDA Approval Process for Bilastine

DateArticle
Jan 14, 2008Inspire Announces Its Termination of Bilastine Licensing Agreement
Jun 20, 2007Inspire and FAES Farma Amend Bilastine Licensing Agreement

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide